Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Double-blind, Two-arm, Mechanism of Action Study to Investigate the Effect of Orforglipron on Body Composition in Adult Participants With Obesity or Overweight, Without Diabetes

NCT06824051 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT06824051
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06824051 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Double-blind, Two-arm, Mechanism of Action Study to Investigate the Effect of Orforglipron on Body Composition in Adult Participants With Obesity or Overweight, Without Diabetes
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Completed
Start date
February 17, 2025
Completion date
January 26, 2026
Enrollment
120 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

obesity, overweight